AstraZeneca Results Presentation Deck
Q1 2021: solid start to the year
Key highlights
Total revenue +11%, incl. 4% from the pandemic COVID-19¹ vaccine. Total revenue excl. vaccine +7%
Growth: Oncology +16% and New CVRM² +15%. Respiratory & Immunology -4%, impacted by stocking in Q1 2020.
Emerging markets +10%
Core operating profit +34%, supported by core 001³ (+146%)
Core EPS4 $1.63 (+53%), incl. 8% tax rate. Impact of pandemic vaccine $(0.03)
Pipeline progress underpins double-digit revenue growth
ESG5: COVID-19 vaccine supplies increasing
Proposed Alexion acquisition passed several competition clearances; shareholder vote 11 May 2021
2021 guidance reiterated: total revenue increase by a low teens percentage, accompanied by faster growth in core EPS
to $4.75 to $5.00
Absolute values at actual exchange rates; changes at constant exchange rates (CER) and for first-quarter (Q1) 2021, unless stated otherwise. Guidance at CER and excludes the COVID-19 vaccine and Alexion. 1. Coronavirus disease; an infectious disease caused by a
newly discovered coronavirus 2. New Cardiovascular, Renal and Metabolism comprising Farxiga, Brilinta, Diabetes and Renal 3. Other operating income 4. Earnings per share 5. Environmental, social and (corporate) governance (topics).
3
6View entire presentation